Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin production

Journal of Lipid Research

Volumn 51, Issue 10, 2010, Pages 2957-2966

  Riederer, Monika ^a   Ojala, Pauli J ^b   Hrzenjak, Andelko ^b   Tritscher, Michaela ^a   Hermansson, Martin ^b   Watzer, Bernhard ^c   Schweer, Horst ^c   Desoye, Gernot ^d   Heinemann, Akos ^d   Frank, Sasa ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Arachidonic acid; Calcium; Cyclooxygenase; Endothelial cell; Phospholipase A2; Prostanoids

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID; ARACHIDONOYL LYSOPHOSPHATIDYLCHOLINE; CALCIUM ION; CARBON 14; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; LINOLEOYL LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLCHOLINE; OLEOYL LYSOPHOSPHATIDYLCHOLINE; PALMITOYL LYSOPHOSPHATIDYLCHOLINE; PROSTACYCLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSOL; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; CYCLOOXYGENASE 2; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MALE; MICE; MICE, INBRED C57BL; RNA, MESSENGER;

EID: 77956804639     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M006536     Document Type: Article

References (60)

1. Ruiperez, V., J. Casas, M. A. Balboa, and J. Balsinde. 2007. Group V phospholipase A2-derived lysophosphatidylcholine mediates cyclooxygenase-2 induction in lipopolysaccharide-stimulated macrophages. J. Immunol. 179: 631-638.
2. Sato, H., R. Kato, Y. Isogai, G. Saka, M. Ohtsuki, Y. Taketomi, K. Yamamoto, K. Tsutsumi, J. Yamada, S. Masuda, et al. 2008. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J. Biol. Chem. 283: 33483-33497.
3. Zalewski, A., and C. Macphee. 2005. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25: 923-931. (Pubitemid 40627835)
4. Rousset, X., B. Vaisman, M. Amar, A. A. Sethi, and A. T. Remaley. 2009. Lecithin:cholesterol acyltransferase - from biochemistry to role in cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 16: 163-171.
5. Parthasarathy, S., U. P. Steinbrecher, J. Barnett, J. L. Witztum, and D. Steinberg. 1985. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA. 82: 3000-3004. (Pubitemid 15097780)
6. Rabini, R. A., R. Galassi, P. Fumelli, N. Dousset, M. L. Solera, P. Valdiguie, G. Curatola, G. Ferretti, M. Taus, and L. Mazzanti. 1994. Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes. 43: 915-919.
7. Subbaiah, P. V., C. H. Chen, J. D. Bagdade, and J. J. Albers. 1985. Substrate specificity of plasma lysolecithin acyltransferase and the molecular species of lecithin formed by the reaction. J. Biol. Chem. 260: 5308-5314.
8. Chen, L., B. Liang, D. E. Froese, S. Liu, J. T. Wong, K. Tran, G. M. Hatch, D. Mymin, E. A. Kroeger, R. Y. Man, et al. 1997. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J. Lipid Res. 38: 546-553.
9. Ojala, P. J., M. Hermansson, M. Tolvanen, K. Polvinen, T. Hirvonen, U. Impola, M. Jauhiainen, P. Somerharju, and J. Parkkinen. 2006. Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry. 45: 14021-14031.
10. Croset, M., N. Brossard, A. Polette, and M. Lagarde. 2000. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem. J. 345: 61-67. (Pubitemid 30060104)
11. Marathe, G. K., A. R. Silva, H. C. de Castro Faria Neto, L. W. Tjoelker, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 2001. Lysophosphatidylcholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids. J. Lipid Res. 42: 1430-1437.
12. Stoll, L. L., H. J. Oskarsson, and A. A. Spector. 1992. Interaction of lysophosphatidylcholine with aortic endothelial cells. Am. J. Physiol. 262: H1853-H1860.
13. Meyer zu Heringdorf, D., and K. H. Jakobs. 2007. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim. Biophys. Acta. 1768: 923-940.
14. Wong, J. T., K. Tran, G. N. Pierce, A. C. Chan, K. O., and P. C. Choy. 1998. Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells. J. Biol. Chem. 273: 6830-6836.
15. Inoue, N., K. Hirata, M. Yamada, Y. Hamamori, Y. Matsuda, H. Akita, and M. Yokoyama. 1992. Lysophosphatidylcholine inhibits bradykinin-induced phosphoinositide hydrolysis and calcium transients in cultured bovine aortic endothelial cells. Circ. Res. 71: 1410-1421.
16. Yokoyama, K., T. Ishibashi, H. Ohkawara, J. Kimura, I. Matsuoka, T. Sakamoto, K. Nagata, K. Sugimoto, S. Sakurada, and Y. Maruyama. 2002. HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. Circulation. 105: 962-967.
17. Prokazova, N. V., N. D. Zvezdina, and A. A. Korotaeva. 1998. Effect of lysophosphatidylcholine on transmembrane signal transduction. Biochemistry-Russia. 63: 31-37.
18. Bassa, B. V., D. D. Roh, N. D. Vaziri, M. A. Kirschenbaum, and V. S. Kamanna. 1999. Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCgamma-1 and tyrosine kinase-Ras pathways. Am. J. Physiol. 277: F328-F337.
19. Kume, N., M. I. Cybulsky, and M. A. Gimbrone, Jr. 1992. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90: 1138-1144.
20. Aiyar, N., J. Disa, Z. Ao, H. Ju, S. Nerurkar, R. N. Willette, C. H. Macphee, D. G. Johns, and S. A. Douglas. 2007. Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells. Mol. Cell. Biochem. 295: 113-120.
21. Zembowicz, A., S. L. Jones, and K. K. Wu. 1995. Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J. Clin. Invest. 96: 1688-1692.
22. Rikitake, Y., K. Hirata, S. Kawashima, S. Takeuchi, Y. Shimokawa, Y. Kojima, N. Inoue, and M. Yokoyama. 2001. Signaling mechanism underlying COX-2 induction by lysophosphatidylcholine. Biochem. Biophys. Res. Commun. 281: 1291-1297.
23. Ludwig, M. G., M. Vanek, D. Guerini, J. A. Gasser, C. E. Jones, U. Junker, H. Hofstetter, R. M. Wolf, and K. Seuwen. 2003. Proton-sensing G-protein-coupled receptors. Nature. 425: 93-98.
24. Tomura, H., C. Mogi, K. Sato, and F. Okajima. 2005. Proton-sensing and lysolipid-sensitive G-protein-coupled receptors: a novel type of multi-functional receptors. Cell. Signal. 17: 1466-1476. (Pubitemid 41253986)
25. Lum, H., J. Qiao, R. J. Walter, F. Huang, P. V. Subbaiah, K. S. Kim, and O. Holian. 2003. Inflammatory stress increases receptor for lysophosphatidylcholine in human microvascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 285: H1786-H1789.
26. Wang, L., C. G. Radu, L. V. Yang, L. A. Bentolila, M. Riedinger, and O. N. Witte. 2005. Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A. Mol. Biol. Cell. 16: 2234-2247.
27. Murakami, N., T. Yokomizo, T. Okuno, and T. Shimizu. 2004. G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J. Biol. Chem. 279: 42484-42491.
28. Zou, Y., C. H. Kim, J. H. Chung, J. Y. Kim, S. W. Chung, M. K. Kim, D. S. Im, J. Lee, B. P. Yu, and H. Y. Chung. 2007. Upregulation of endothelial adhesion molecules by lysophosphatidylcholine. Involvement of G protein-coupled receptor GPR4. FEBS J. 274: 2573-2584.
29. Qiao, J., F. Huang, R. P. Naikawadi, K. S. Kim, T. Said, and H. Lum. 2006. Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L91-L101.
30. Sin, W. C., Y. Zhang, W. Zhong, S. Adhikarakunnathu, S. Powers, T. Hoey, S. An, and J. Yang. 2004. G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers. Oncogene. 23: 6299-6303.
31. Bektas, M., L. S. Barak, P. S. Jolly, H. Liu, K. R. Lynch, E. Lacana, K. B. Suhr, S. Milstien, and S. Spiegel. 2003. The G protein-coupled receptor GPR4 suppresses ERK activation in a ligand-independent manner. Biochemistry. 42: 12181-12191.
32. Tobo, M., H. Tomura, C. Mogi, J. Q. Wang, J. P. Liu, M. Komachi, A. Damirin, T. Kimura, N. Murata, H. Kurose, et al. 2007. Previously postulated "ligand-independent" signaling of GPR4 is mediated through proton-sensing mechanisms. Cell. Signal. 19: 1745-1753.
33. Ghosh, M., H. Wang, Y. Ai, E. Romeo, J. P. Luyendyk, J. M. Peters, N. Mackman, S. K. Dey, and T. Hla. 2007. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J. Exp. Med. 204: 2053-2061.
34. McAdam, B. F., F. Catella-Lawson, I. A. Mardini, S. Kapoor, J. A. Lawson, and G. A. FitzGerald. 1999. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA. 96: 272-277. [Erratum. 1999. Proc. Natl. Acad. Sci. USA. 96: 5890.]
35. Alfranca, A., M. A. Iniguez, M. Fresno, and J. M. Redondo. 2006. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc. Res. 70: 446-456.
36. Dogne, J. M., J. Hanson, and D. Pratico. 2005. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol. Sci. 26: 639-644.
37. Ueno, N., Y. Takegoshi, D. Kamei, I. Kudo, and M. Murakami. 2005. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem. Biophys. Res. Commun. 338: 70-76. (Pubitemid 41540538)
38. Hirata, K., H. L. Dichek, J. A. Cioffi, S. Y. Choi, N. J. Leeper, L. Quintana, G. S. Kronmal, A. D. Cooper, and T. Quertermous. 1999. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J. Biol. Chem. 274: 14170-14175.
39. Jaye, M., K. J. Lynch, J. Krawiec, D. Marchadier, C. Maugeais, K. Doan, V. South, D. Amin, M. Perrone, and D. J. Rader. 1999. A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 21: 424-428.
40. Gauster, M., G. Rechberger, A. Sovic, G. Horl, E. Steyrer, W. Sattler, and S. Frank. 2005. Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine. J. Lipid Res. 46: 1517-1525. (Pubitemid 43109817)
41. Ojala, P. J., T. E. Hirvonen, M. Hermansson, P. Somerharju, and J. Parkkinen. 2007. Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils. J. Leukoc. Biol. 82: 1501-1509.
42. Schweer, H., B. Watzer, and H. W. Seyberth. 1994. Determination of seven prostanoids in 1 ml of urine by gas chromatographynegative ion chemical ionization triple stage quadrupole mass spectrometry. J. Chromatogr. 652: 221-227.
43. Kim, Y. L., Y. J. Im, N. C. Ha, and D. S. Im. 2007. Albumin inhibits cytotoxic activity of lysophosphatidylcholine by direct binding. Prostaglandins Other Lipid Mediat. 83: 130-138.
44. Tan, X., S. Essengue, J. Talreja, J. Reese, D. J. Stechschulte, and K. N. Dileepan. 2007. Histamine directly and synergistically with lipopolysaccharide stimulates cyclooxygenase-2 expression and prostaglandin I(2) and E(2) production in human coronary artery endothelial cells. J. Immunol. 179: 7899-7906.
45. Camacho, M., J. Lopez-Belmonte, and L. Vila. 1998. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ. Res. 83: 353-365. (Pubitemid 28389965)
46. Kearney, P. M., C. Baigent, J. Godwin, H. Halls, J. R. Emberson, and C. Patrono. 2006. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 332: 1302-1308.
47. McGettigan, P., and D. Henry. 2006. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 296: 1633-1644.
48. Solomon, S. D., M. A. Pfeffer, J. J. V. McMurray, R. Fowler, P. Finn, B. Levin, C. Eagle, E. Hawk, M. Lechuga, A. G. Zauber, et al. 2006. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 114: 1028-1035.
49. de Carvalho, M. G., J. Garritano, and C. C. Leslie. 1995. Regulation of lysophospholipase activity of the 85-kDa phospholipase A2 and activation in mouse peritoneal macrophages. J. Biol. Chem. 270: 20439-20446.
50. Moore, S. A., E. Yoder, and A. A. Spector. 1990. Role of the bloodbrain barrier in the formation of long-chain omega-3 and omega-6 fatty acids from essential fatty acid precursors. J. Neurochem. 55: 391-402.
51. Grammatikos, S. I., P. V. Subbaiah, T. A. Victor, and W. M. Miller. 1994. Diversity in the ability of cultured cells to elongate and desaturate essential (n-6 and n-3) fatty acids. Ann. N. Y. Acad. Sci. 745: 92-105.
52. Hirabayashi, T., K. Kume, K. Hirose, T. Yokomizo, M. Iino, H. Itoh, and T. Shimizu. 1999. Critical duration of intracellular Ca2+ response required for continuous translocation and activation of cytosolic phospholipase A2. J. Biol. Chem. 274: 5163-5169.
53. Boittin, F. X., F. Gribi, K. Serir, and J. L. Beny. 2008. Ca2+-independent PLA2 controls endothelial store-operated Ca2+ entry and vascular tone in intact aorta. Am. J. Physiol. Heart Circ. Physiol. 295: H2466-H2474.
54. Wolfram Kuhlmann, C. R., D. Wiebke Ludders, C. A. Schaefer, A. Kerstin Most, U. Backenkohler, T. Neumann, H. Tillmanns, and A. Erdogan. 2004. Lysophosphatidylcholine-induced modulation of Ca(2+)-activated K(+)channels contributes to ROS-dependent proliferation of cultured human endothelial cells. J. Mol. Cell. Cardiol. 36: 675-682.
55. Huang, F., P. V. Subbaiah, O. Holian, J. Zhang, A. Johnson, N. Gertzberg, and H. Lum. 2005. Lysophosphatidylcholine increases endothelial permeability: role of PKCalpha and RhoA cross talk. [see comment] Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L176-L185. [Comment. 2005. Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L174-L175.]
56. Vuong, T. D., B. Braam, N. Willekes-Koolschijn, P. Boer, H. A. Koomans, and J. A. Joles. 2003. Hypoalbuminaemia enhances the renal vasoconstrictor effect of lysophosphatidylcholine. Nephrol. Dial. Transplant. 18: 1485-1492.
57. Murugesan, G., M. R. Sandhya Rani, C. E. Gerber, C. Mukhopadhyay, R. M. Ransohoff, G. M. Chisolm, and K. Kottke-Marchant. 2003. Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. J. Mol. Cell. Cardiol. 35: 1375-1384. (Pubitemid 37336565)
58. Paradis, M. E., K. O. Badellino, D. J. Rader, Y. Deshaies, P. Couture, W. R. Archer, N. Bergeron, and B. Lamarche. 2006. Endothelial lipase is associated with inflammation in humans. J. Lipid Res. 47: 2808-2813.
59. Badellino, K. O., M. L. Wolfe, M. P. Reilly, and D. J. Rader. 2008. Endothelial lipase is increased in vivo by inflammation in humans. Circulation. 117: 678-685.
60. Triggiani, M., F. Granata, A. Frattini, and G. Marone. 2006. Activation of human inflammatory cells by secreted phospholipases A2. Biochim. Biophys. Acta. 1761: 1289-1300.